Key result
SGLT2is reduced heart failure, GLP1RAs increased deep vein thrombosis, and DPP4is reduced peripheral ischaemia.
Why the study?
The associations between three new categories of hypoglycaemic drugs (DPP4is, GLP1RAs, and SGLT2is) and various cardiovascular diseases needed to be defined.
Do new hypoglycaemic agents (DPP4is, GLP1RAs, SGLT2is) alter the risk of various cardiovascular diseases compared to placebo?
Meta-Analysis
Do new hypoglycaemic agents (DPP4is, GLP1RAs, SGLT2is) alter the risk of various cardiovascular diseases compared to placebo?
Answers are grounded in this paper and cite their sources.
Different classes of novel hypoglycemic agents have distinct cardiovascular profiles, with SGLT2 inhibitors showing broad cardiovascular benefits including reduced heart failure and atrial fibrillation, while GLP1 receptor agonists may increase the risk of deep vein thrombosis.
WHAT IS KNOWN AND OBJECTIVE: New hypoglycaemic agents consist of dipeptidyl peptidase four inhibitors (DPP4is), glucagon-like peptide one receptor agonists (GLP1RAs) and sodium-glucose cotransporter two inhibitors (SGLT2is). We aimed to define the association between each category of these new hypoglycaemic drugs and various cardiovascular diseases. METHODS: Large randomized trials comparing DPP4is, GLP1RAs or SGLT2is with placebo were included. Outcomes of interest were 95 kinds of cardiovascular diseases. Meta-analysis was conducted to generate pooled risk ratio (RR) and 95% confidence interval (CI). RESULTS AND DISCUSSION: Twenty-one large randomized trials were included in this meta-analysis. Compared with placebo, SGLT2is were associated with the lower risks of hypertension (RR 0.67, 95% CI 0.49-0.93), atrial fibrillation (RR 0.78, 95% CI 0.67-0.91), bradycardia (RR 0.60, 95% CI 0.40-0.89) and heart failure (RR 0.74, 95% CI 0.68-0.80); GLP1RAs were associated with the lower risk of peripheral arterial occlusive disease (RR 0.73, 95% CI 0.56-0.97) and with the higher risk of deep vein thrombosis (RR 2.12, 95% CI 1.32-3.4), while DPP4is were associated with the lower risk of peripheral ischaemia (RR 0.57, 95% CI 0.37-0.89). WHAT IS NEW AND CONCLUSIONS: Our meta-analysis revealed that SGLT2is were associated with the lower risks of hypertension, atrial fibrillation, bradycardia and heart failure; GLP1RAs were associated with the lower risk of peripheral arterial occlusive disease and with the higher risk of deep vein thrombosis, while DPP4is were associated with the lower risk of peripheral ischaemia. These findings propose that each category of these new hypoglycaemic agents should be avoided or preferred in patients at high risks of specific cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Liao et al. (2021) conducted a meta-analysis in Cardiovascular diseases. DPP4is, GLP1RAs, and SGLT2is vs. Placebo was evaluated on Heart failure (SGLT2is vs placebo) (RR 0.74, 95% CI 0.68-0.80). SGLT2is reduced heart failure, GLP1RAs increased deep vein thrombosis, and DPP4is reduced peripheral ischaemia.
Synapse has enriched 10 related papers. Consider them for comparative context: